Ann Dermatol.
2023 May;35(Suppl1):S107-S111. 10.5021/ad.21.060.
Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
- Affiliations
-
- 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- KMID: 2542753
- DOI: http://doi.org/10.5021/ad.21.060
Abstract
- Pyoderma gangrenosum is one of the dermatological extra-intestinal manifestations of ulcerative colitis (UC). We report a case of a 26-year-old male patient suffering from relapsed UC with a newly developed pyoderma gangrenosum. His skin and intestinal symptoms were intractable to treatment with steroids, immunosuppressants, or a single biological agent such as infliximab, golimumab, or vedolizumab. For the first time in Korea, we report a successful treatment experience of pyoderma gangrenosum in UC using dual biological agents, vedolizumab and infliximab. We strategically targeted each of the intestinal and skin symptoms, with a specific biological agent based on the drug’s mechanism of action.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Post-traumatic Pyoderma Gangrenosum Associated with Ulcerative Colitis
- A Case of Pyoderma Gangrenosum Associated with Ulcerative Colitis
- Multiple Pyoderma Gangrenosum in Ulcerative Colitis
- A Case of Simultaneous Presentation of Bullous and Ulcerative Types of Pyoderma Gangrenosum in an Ulcerative Colitis Patient
- Hyperbaric Oxygen Therapy in Pyoderma Gangrenosum
